A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age
Latest Information Update: 07 Jul 2025
At a glance
- Drugs MRNA-1403 (Primary)
- Indications Norovirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms NOVA-301
- Sponsors Moderna Therapeutics
Most Recent Events
- 29 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 13 Jan 2025 According to a Moderna media release, The Company anticipates efficacy data from the study in 2025 if sufficient cases are accrued in the first season; otherwise, the study will continue to a second season.
- 07 Nov 2024 According to a Moderna media release, company initiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenza.